Class 3 MHRA drug alert – Lynparza (olaparib) 50mg capsules (AstraZeneca)

Class 3 MHRA drug alert – Lynparza (olaparib) 50mg capsules (AstraZeneca)

March 12, 2018

Drug alert number: EL (18)A/ 06

Date issued: 12th March 2018

The Medicines and Healthcare products regulatory Agency (MHRA) has issued a class 3 pharmacy and wholesaler level recall for certain batches of:

Lynparza (olaparib) 50mg capsules (AstraZeneca), pack size: 4 x 112 capsules

AstraZeneca is recalling one specific batch as the level of olaparib polymorphic form L exceeds the registered specification limit. As a precautionary measure, certain other batches are also being recalled as they may exceed the limit before the end of their shelf life.

Healthcare professionals are advised to stop dispensing the batches affected and return all remaining stock of these batches to suppliers.

To view the alert please visit the website.

Posted in: ,

More Latest News >

Menadiol 10mg tablets supply issue

PSNC has become aware that Alliance Pharmaceuticals Ltd has transferred the production of its licensed Menadiol Diphosphate Tablets 10mg to...

Health & Care Review

Plans to cut excess calorie consumption unveiled Public Health England (PHE) has announced new measures to help reduce people’s excessive...